MEQUON, Wis.–(BUSINESS WIRE)–Titan Spine announced that it will begin full commercial release of its new Endoskeleton® TC system first quarter of 2011. The Endoskeleton® TC is an interbody fusion device for the cervical spine. The product received 510(k) clearance in July of this year and has been in limited market release since early August. The device has an acid etched titanium surface and is biomechanically designed to promote spinal fusion.
“The design and technology utilized cater to the biology of healing”
Dr. Tom Wascher, neurosurgeon at the NeuroSpine Center of Wisconsin, said, “In comparison to currently available cervical interbody products, this device has several advantages. It has a large open aperture for bone graft insertion, excellent initial fixation to the bone, and has the versatility of several different footprints including the widest available footprint on the market. The combination of these factors provides for excellent mechanical stability increasing the likelihood of a solid fusion.”
This represents the third regulatory clearance for Titan Spine as the company continues to build its portfolio of bioactive spinal interbody fusion devices. “The design and technology utilized cater to the biology of healing,” stated Jennifer Schneider, Sr. Research and Development Engineer. “Titan Spine is pleased to offer a device that presents unique benefits to providing treatment for patients with degenerative disc disease in the cervical spine.”
Surgeons are excited to learn about the bony ingrowth benefits the Endoskeleton® TC provides especially at a time when the use of BMP and plastic devices are under scrutiny.
About Titan Spine – Titan Spine, LLC is a privately owned company in Mequon, Wisconsin focusing on the design and manufacturing of bioactive interbody fusion devices for the spine. Founded in 2005, the company is committed to developing advanced products for treatment of various pathologies that cause back pain.
